[ORGANIZATION]
Sarepta Therapeutics
Featured in 2 tracked stories · first seen
Situations
Duchenne muscular dystrophy drug regulation in Brazil
2 clusters · 27 sources · last updated
Latest: Anvisa and Roche cancel Elevidys registration in Brazil
In August 2026, Brazil’s National Health Surveillance Agency (Anvisa) issued two significant regulatory decisions regarding treatments for Duchenne muscular dystrophy (DMD). First, Anvisa approved the registration of Du
Cerus Corp earnings and product outlook
2 clusters · 5 sources · last updated
Latest: Sarepta Therapeutics Reports Q2 Revenue Decline and Revised Outlook
Cerus Corporation reported second‑quarter 2026 results that met analysts' expectations, posting earnings per share of $0.01 on revenue of $63.3 million. Product revenue rose 10% to $57.4 million, driving a 16% year‑over‑